Table 1 Patient demographics and baseline characteristics.
From: A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
Characteristic | Melanoma (n = 20) | MTC (n = 13) | GBM (n = 23) | Other solid tumor (n = 43) | Pooled NEC/NET (n = 101) | All treated patients (N = 200) |
|---|---|---|---|---|---|---|
Median age (range), years | 63.5 (40–78) | 60 (33–67) | 57 (36–72) | 64 (28–84) | 61 (28–82) | 61 (28–84) |
Male sex, n (%) | 10 (50) | 8 (62) | 19 (83) | 23 (53) | 66 (65) | 126 (63) |
ECOG performance status, n (%) | ||||||
0 | 7 (35) | 1 (8) | 1 (4) | 5 (12) | 20 (20) | 34 (17) |
1 | 13 (65) | 12 (92) | 22 (96) | 38 (88) | 80 (79) | 165 (83) |
2 | 0 | 0 | 0 | 0 | 1 (1) | 1 (1) |
Disease stage at study entry | ||||||
Stage IIa | 1 (5) | 0 | 0 | 0 | 0 | 1 (1) |
Stage IIb | 0 | 0 | 0 | 2 (5) | 0 | 2 (1) |
Stage IIIa | 0 | 0 | 0 | 1 (2) | 3 (3) | 4 (2) |
Stage IIIb | 0 | 0 | 0 | 0 | 2 (2) | 2 (1) |
Stage IIIc | 1 (5) | 0 | 0 | 1 (2) | 0 | 2 (1) |
Stage IV | 18 (90) | 12 (92) | 23 (100) | 39 (91) | 95 (94) | 187 (94) |
Missing | 0 | 1 (8) | 0 | 0 | 1 (1) | 2 (1) |
DLL3 level, n (%) | ||||||
High (≥50%) | 5 (25) | 6 (46) | 2 (9) | 11 (26) | 53 (52) | 77 (39) |
Low (1–49%) | 14 (70) | 7 (54) | 21 (91) | 32 (74) | 48 (48) | 122 (61) |
0% | 1 (5)a | 0 | 0 | 0 | 0 | 1 (0.5) |
Prior lines of therapy, n (%) | ||||||
1 | 3 (15) | 4 (31) | 2 (9) | 6 (14) | 22 (22) | 37 (19) |
2 | 4 (20) | 4 (31) | 7 (30) | 10 (23) | 25 (25) | 50 (25) |
3 | 5 (25) | 0 | 6 (26) | 8 (19) | 27 (27) | 46 (23) |
≥4 | 8 (40) | 2 (15) | 8 (35) | 19 (44) | 27 (27) | 64 (32) |
Missing | 0 | 3 (23) | 0 | 0 | 0 | 3 (2) |
Response to first-line therapy, n (%)b | ||||||
Sensitivec | 4 (20) | 1 (8) | 4 (17) | 15 (35) | 33 (33) | 57 (29) |
Resistantd | 3 (15) | 4 (31) | 4 (17) | 3 (7) | 17 (17) | 31 (16) |
Refractorye | 7 (35) | 2 (15) | 5 (22) | 12 (28) | 19 (19) | 45 (23) |
Undetermined | 6 (30) | 6 (46) | 10 (43) | 13 (30) | 32 (32) | 67 (34) |
